The Center for Breakthrough Medicines (CBM), a contract development, manufacturing, and testing organization (CDMO) is packaging their preclinical capabilities into an IND-enabling offering to help innovator companies manufacture high quality drug substance and drug product for preclinical studies needed for IND-enabling activities. Preclinical assessment of investigational cell and gene therapy products is a critical milestone to move programs forward while balancing limited capital allocate...